Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xianglian herbal combination is a topical Traditional Chinese Medicine (TCM) therapy developed by the Guangdong Provincial Hospital of TCM for the treatment of tinea pedis (athlete's foot). The combination typically consists of a solution and an ointment or cream formulation, primarily derived from the herbs *Coptis chinensis* (Huang Lian) and *Aucklandia lappa* (Mu Xiang). The therapeutic efficacy is largely attributed to berberine and other protoberberine alkaloids found in *Coptis chinensis*, which exhibit broad-spectrum antifungal activity by disrupting fungal cell membrane integrity and inhibiting nucleic acid synthesis. *Aucklandia lappa* provides complementary antimicrobial and anti-inflammatory effects through its sesquiterpene lactone constituents. This herbal regimen has been clinically evaluated in randomized controlled trials as an alternative to conventional synthetic antifungal treatments like terbinafine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xianglian herbal combination.